Literature DB >> 7745415

Peripheral neuropathy associated with simvastatin.

T Phan1, J G McLeod, J D Pollard, O Peiris, A Rohan, J P Halpern.   

Abstract

Four patients are described who developed sensorimotor neuropathy while being treated with simvastatin and had complete or partial resolution of clinical abnormalities after withdrawal of treatment. In one case onset was within days of commencing treatment, but in two cases symptoms did not develop for two years. The electrophysiological and pathological features of the neuropathy were those of axonal degeneration. Clinical evidence of proximal and distal weakness and muscle fasciculations and persistent abnormalities of sensory conduction after recovery suggest the possibility of toxic damage to anterior horn cells and dorsal root ganglia. Thirty eight other cases with symptoms suggestive of peripheral neuropathy have been reported to the Australian Adverse Drug Reactions Advisory Committee, 22 of whom recovered after cessation of treatment; in five cases there was recurrence after re-exposure to the drug. Simvastatin should be considered among the causes of peripheral neuropathy, and the drug should be withdrawn if patients receiving it develop muscle weakness or sensory disturbances.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7745415      PMCID: PMC1073498          DOI: 10.1136/jnnp.58.5.625

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  7 in total

1.  Muscle side effects associated with simvastatin therapy.

Authors:  J D England; A Viles; J C Walsh; P M Stewart
Journal:  Med J Aust       Date:  1990-11-05       Impact factor: 7.738

2.  Massive rhabdomyolysis and simvastatin.

Authors:  N Bizzaro; E Bagolin; L Milani; C Cereser; B Finco
Journal:  Clin Chem       Date:  1992-08       Impact factor: 8.327

3.  Lovastatin, isoprenes, and myopathy.

Authors:  P A Walravens; C Greene; F E Frerman
Journal:  Lancet       Date:  1989-11-04       Impact factor: 79.321

4.  Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.

Authors:  H Mabuchi; T Haba; R Tatami; S Miyamoto; Y Sakai; T Wakasugi; A Watanabe; J Koizumi; R Takeda
Journal:  N Engl J Med       Date:  1981-08-27       Impact factor: 91.245

Review 5.  Efficacy and tolerability of simvastatin (MK-733).

Authors:  A F Stalenhoef; M J Mol; P M Stuyt
Journal:  Am J Med       Date:  1989-10-16       Impact factor: 4.965

6.  Simvastatin: the clinical profile.

Authors:  J F Walker
Journal:  Am J Med       Date:  1989-10-16       Impact factor: 4.965

7.  Long-term safety and efficacy profile of simvastatin.

Authors:  S J Boccuzzi; T S Bocanegra; J F Walker; D R Shapiro; M E Keegan
Journal:  Am J Cardiol       Date:  1991-11-01       Impact factor: 2.778

  7 in total
  16 in total

1.  Effect of simvastatin on sensorial, motor, and morphological parameters in sciatic nerve crush induced-neuropathic pain in rats.

Authors:  Claudia Rita Corso; Daniel Fernandes Martins; Stephanie Carvalho Borges; Olair Carlos Beltrame; José Ederaldo Queiroz Telles; Nilza Cristina Buttow; Maria Fernanda de Paula Werner
Journal:  Inflammopharmacology       Date:  2017-11-29       Impact factor: 4.473

2.  Association between statin use and Bell's palsy: a population-based study.

Authors:  Shih-Han Hung; Li-Hsuan Wang; Herng-Ching Lin; Shiu-Dong Chung
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

Review 3.  HMG-CoA reductase inhibitors and myotoxicity.

Authors:  M Ucar; T Mjörndal; R Dahlqvist
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

4.  Statins and polyneuropathy revisited: case-control study in Denmark, 1999-2013.

Authors:  Toke de Koning Svendsen; Peter Nørregaard Hansen; Luis Alberto García Rodríguez; Lene Andersen; Jesper Hallas; Søren Hein Sindrup; David Gaist
Journal:  Br J Clin Pharmacol       Date:  2017-05-11       Impact factor: 4.335

Review 5.  Update on medication-induced peripheral neuropathy.

Authors:  Louis H Weimer; Noor Sachdev
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

6.  Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance.

Authors:  Beatrice A Golomb; John J McGraw; Marcella A Evans; Joel E Dimsdale
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 7.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

Review 8.  Medication-induced peripheral neuropathy.

Authors:  Louis H Weimer
Journal:  Curr Neurol Neurosci Rep       Date:  2003-01       Impact factor: 5.081

9.  Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases.

Authors:  Giovanni Corrao; Antonella Zambon; Lorenza Bertù; Edoardo Botteri; Olivia Leoni; Paolo Contiero
Journal:  J Epidemiol Community Health       Date:  2004-12       Impact factor: 3.710

10.  Inhibition of pancreatic cholesterol esterase reduces cholesterol absorption in the hamster.

Authors:  John E Heidrich; Linda M Contos; Lucy A Hunsaker; Lorraine M Deck; David L Vander Jagt
Journal:  BMC Pharmacol       Date:  2004-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.